跳到正文
原文
Medical Xpress·· 2026-10-02AI 评分56

iPSC来源3D类脑模型用于多发性硬化髓鞘损伤与再生研究,提供新工具用于MS药物筛选

'Mini-brains' model myelin damage and regeneration, offering new tool for MS drug testing

AI 导读

澳大利亚和纽西兰团队开发了一种米粒大小的3D类脑模型(mini-brains),用于模拟多发性硬化(MS)中髓鞘破坏(脱髓鞘)和再生(再髓鞘化)过程。该模型由重编程的成体干细胞(iPSC)衍生的球体构建,含有小胶质细胞等免疫细胞,可触发类似MS的髓鞘损伤。该工作发表于Nature Neuroscience,作者称此模型为研究髓鞘损伤机制及筛选保护或修复髓鞘药物的新平台。

正文
'Mini-brains' model myelin damage and regeneration, offering new tool for MS drug testing
iPSC-derived spheroids that contain microglia continue to show extensive myelinated axon networks. Credit: Nature Neuroscience (2026). DOI: 10.1038/s41593-026-02457-z

Researchers have developed 3D "mini-brains" they hope will help speed up the search for much-needed drug treatments for multiple sclerosis (MS), an autoimmune condition affecting almost 3 million people worldwide. Their research has been published in the journal Nature Neuroscience.

Led by The Florey Institute of Neuroscience and Mental Health and Monash University, scientists from Australia and New Zealand have used reprogrammed adult stem cells to engineer the human-like central nervous system cell model, which is the size of a grain of rice.

Among only a handful of MS organoids created globally, the "mini-brains" give researchers a highly detailed cellular view of myelin destruction (demyelination) and regeneration (remyelination) in human cells.

Myelin is a fatty sheath that covers and protects nerve fibers and allows messages, via electrical impulses, to travel quickly around the brain, spinal cord and the rest of the body. In MS, the immune system mistakenly attacks myelin, causing nerve damage, neurological symptoms and, over time, disability.

Immune cells inside the 'mini brains'. Credit: Associate Professor Samantha Barton. © Copyright - only use with this story

There are currently no therapies available that repair this damage. Existing MS medications are only able to treat symptoms and slow progression.

Recreating myelin damage in human cells

Associate professor Samantha Barton, who leads the Myelin in Health and Disease Group at The Florey, said the cell model took more than six years to engineer and is a significant step forward in MS research.

"In science, we typically use rodents to model diseases for research, but drugs identified to work in these models of disease are rarely effective in people, so creating more human-relevant model systems is important," Barton said.

"The relevance of our new system is significant. In addition to generating myelin, we have been able to introduce immune cells to trigger injury similar to MS. This gives us the unique opportunity to study the regenerative process of remyelination in the laboratory.

"This model can help researchers better understand what drives myelin damage and repair in MS and it also gives us a new platform to screen drugs that protect or restore myelin.

"The dream is to find new ways to slow or prevent MS progression—we hope our models could help us do that."

The project involved experts from The Florey, University of Melbourne, University of Auckland, Monash University, WEHI and University of Canberra.

Testing drugs and boosting repair

Dr. Shwathy Ramesan, first author and a postdoctoral fellow at The Florey, said the cell model was a game-changer because it will allow researchers to see drugs working in near real time on human cells.

"We are extremely happy with our findings and believe we are closer than ever to creating the best possible platform for MS drug development with the aim of reversing the disease and giving quality health back to people living with MS," Ramesan said.

"After years of developing and refining this model, it's exciting to see it provide a window into human myelin biology that wasn't previously available. We hope it becomes a valuable tool not only for our team but for researchers studying MS around the world."

Co-senior author and associate professor David Gonsalvez from Monash University said this new technology enables researchers to explore potential therapeutics that may directly improve endogenous repair processes by human cells, leading to better treatments for diseases like MS.

"We are excited at the prospect of using our new system to identify therapeutics that can actually boost the limited ability we humans all possess to repair our electrical insulation in the central nervous system," Gonsalvez said.

Publication details

Shwathy Ramesan et al, A human-induced pluripotent stem cell-derived spheroid model to investigate myelin injury and repair, Nature Neuroscience (2026). DOI: 10.1038/s41593-026-02457-z

Journal information: Nature Neuroscience

Clinical categories

Neurology

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: 'Mini-brains' model myelin damage and regeneration, offering new tool for MS drug testing (2026, October 1) retrieved 1 October 2026 from https://medicalxpress.com/news/2026-10-mini-brains-myelin-regeneration-tool.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com